Sepracor filings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm submits NDA March 9 for Soltara (norastemizole 30 mg capsules) for treatment of allergic rhinitis. Sepracor is also developing a Soltara pseudoephedrine combo product, a syrup and a rapidly dissolving tablet. On March 30, the firm submitted an sNDA for a lower dosage strength of its inhaled drug Xopenex (levalbuterol) for prevention of bronchospasm in children aged 4 to 11. The drug currently is indicated for patients 12 and older. Sepracor plans a fourth quarter filing for the sleep disorders agent (s)-zopicolon
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.